Volume 5 Issue 2
Mar.  2014
Turn off MathJax
Article Contents
Article Navigation >  ORGAN TRANSPLANTATION  > 2014  >  5(2): 74-78
Du Guosheng, Zhou Lin, Shi Bingyi, et al. Clinical study of triple anti-tumor therapy for preventing tumor recurrence of terminal primary liver cancer after liver transplantation[J]. ORGAN TRANSPLANTATION, 2014, 5(2): 74-78. doi: 10.3969/j.issn.1674-7445.2014.02.004
Citation: Du Guosheng, Zhou Lin, Shi Bingyi, et al. Clinical study of triple anti-tumor therapy for preventing tumor recurrence of terminal primary liver cancer after liver transplantation[J]. ORGAN TRANSPLANTATION, 2014, 5(2): 74-78. doi: 10.3969/j.issn.1674-7445.2014.02.004
shu

Clinical study of triple anti-tumor therapy for preventing tumor recurrence of terminal primary liver cancer after liver transplantation

doi: 10.3969/j.issn.1674-7445.2014.02.004
  • 1.

    Department of Hepatobiliary Surgery, the 309th Hospital of Chinese People's Liberation Army, Beijing 100091, China

  • Received Date: 2014-01-05
    Available Online: 2021-01-26
  • Publish Date: 2014-03-15
    Abstract
  •   Objective   To investigate initially the availability and safety of combined application of sirolimus, thymosin α-1(Tα-1) and Huaier granule in preventing tumor recurrence of terminal primary liver cancer(TPLC) after liver transplantation(LT).   Methods   Combination group included 12 patients with TPLC who underwent LT in the 309th hospital of Chinese People's Liberation Army from 2010 to 2012(all conform to Hangzhou standard). And historical control group included 15 patients with TPLC underwent LT at the same hospital from 2002 to 2006, whose follow up data was true and precise. During 1 month after LT, the type or dose of immunosuppressors was adjusted according to the individual differences of patients. Tacrolimus(FK506) and mycophenolate mofetil(MMF) were given to patients at first, and FK506 was gradually withdrawn and insteaded by sirolimus at 1 month after LT. Methylprednisolone of 500 mg was given during operation. Then small dose of methylprednisolone was given after operation and withdrawn at 1 week after LT. At the same time Tα-1 and Huaier Granule were added. The Tα-1 was injected for 10 days(1.6 mg per time, once a day), and after that injected twice a week. Huaier granule was given 20 g per time and three times a day. All the patients had been followed up. All the data including serum alpha-fetoprotein(AFP) changes, occurrence of allograft rejection, recurrence and treatment, survival time were collected accurately.   Results   In the combination group, the 12 cases were followed up for 8-35 months with the median follow up time of 18 months without loss or drop-out. All patients were survived. In the historical control group, the medium follow up time was 14 months till all the patients died. In the combination group, 2 cases developed isolated pulmonary metastasis after LT and 2 cases deveoped multiple pulmonary metastasis. All of the four cases were cured with the treatment of γ-knife. In history control group, 7 cases developed recurrence in 6 months after LT and all of the 15 cases developed recurrence in 1 year after LT. All of the 15 cases developed pulmonary metastasis(6 cases were isolated and 9 cases were multiple). All cases died of multi-section of tumor metastasis.   Conclusions   Combined application of sirolimus, Tα-1 and Huaier granule have significantly effect on preventing tumor recurrence of TPLC after LT, delaying tumor recurrence and prolonging survival time of patients.

     

    • FullText(HTML)
  • loading
    • References(16)
  • [1]
    Toso C, Merani S, Bigam DL, et al. Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma[J]. Hepatology,2010,51(4):1237-1243. doi: 10.1002/hep.23437
    [2]
    田晓辉,薛武军,田普训,等.钙调磷酸酶抑制剂转换为西罗莫司治疗慢性移植物肾病的疗效研究[J]. 器官移植,2012,3(6):320-323. http://www.organtranspl.com/browse/detail/qkid/61/id/632.html

    Tian XH, Xue WJ, Tian PX, et al. Effect of conversion from calcineurin inhibitor to sirolimus on chronic allograft nephropathy[J]. Organ Transplant,2012,3(6):320-323. http://www.organtranspl.com/browse/detail/qkid/61/id/632.html
    [3]
    许世磊,张英才,易慧敏,等.西罗莫司应用于肝癌肝移植受者的疗效分析[J].中华器官移植杂志,2013,34(8):481-485.

    Xu SL, Zhang YC, Yi HM, et al. The influence of sirolimus-based immnosuppression on hepatocellular carcinoma recurrence post-liver transplantation[J]. Chin J Organ Transplant,2013,34(8):481-485.
    [4]
    Jimenez RH, Boylan JM, Lee JS, et al. Rapamycin response in tumorigenic and non-tumorigenic hepatic cell lines[J]. PLoS One,2009,4(10):e7373. doi: 10.1371/journal.pone.0007373
    [5]
    Basu A, Liu T, Banerjee P, et al. Effectiveness of a combination therapy using calcineurin inhibitor and mTOR inhibitor in preventing allograft rejection and post-transplantation renal cancer progression[J]. Cancer Lett, 2012, 321(2):179-186. doi: 10.1016/j.canlet.2012.02.004
    [6]
    黄炜,严律南,吴泓,等.槐耳颗粒在肝癌肝移植患者术后临床应用价值的回顾性队列研究[J].中国普外基础与临床杂志,2010,17(6):547-551. http://www.cnki.com.cn/Article/CJFDTOTAL-ZPWL201006009.htm

    Huang W, Yan LN, Wu H, et al. Retrospective cohort study on clinical value of huaier granule in postoperative patients with liver transplantation for hepatocellular carcinoma[J]. Chin J Bases Clin Gen Surg,2010,17(6):547-551. http://www.cnki.com.cn/Article/CJFDTOTAL-ZPWL201006009.htm
    [7]
    李立新,叶胜龙,王艳红,等.槐耳浸膏对人肝癌高转移细胞系转移的抑制作用研究[J].中国肿瘤,2006,15(4):265-268. http://www.cnki.com.cn/Article/CJFDTOTAL-ZHLU200604015.htm

    Li LX, Ye SL, Wang YH, et al. Metastatic potential inhibited with trametes robiniophila in highly metastatic potential human hepatocellular carcinoma cells lines[J]. Chin Cancer,2006,15(4):265-268. http://www.cnki.com.cn/Article/CJFDTOTAL-ZHLU200604015.htm
    [8]
    莫斌,杨家印,严律南,等.槐耳颗粒用于肝癌肝移植术后的临床观察[J].四川大学学报:医学版,2011,42(5):739-741. http://www.cnki.com.cn/Article/CJFDTOTAL-HXYK201105038.htm

    Mo B, Yang JY, Ya LN, et al. Clinical observation of huaier granule on hepatocellular carcinoma after liver transplantation[J]. J Sichuan Univ: Medical Science Edition,2011,42(5):739-741. http://www.cnki.com.cn/Article/CJFDTOTAL-HXYK201105038.htm
    [9]
    Goldstein AL, Goldstein AL. From lab to bedside: emerging clinical applications of thymosin alpha 1[J]. Expert Opin Biol Ther,2009,9(5):593-608. doi: 10.1517/14712590902911412
    [10]
    Serafino A, Pierimarchi P, Pica F, et al. Thymosin α1 as a stimulatory agent of innate cell-mediated immune response[J]. Ann N Y Acad Sci,2012,1270:13-20. doi: 10.1111/nyas.2012.1270.issue-1
    [11]
    Garaci E, Pica F, Serafino A, et al. Thymosin α1 and cancer: action on immune effector and tumor target cells[J]. Ann N Y Acad Sci,2012,1269:26-33. doi: 10.1111/j.1749-6632.2012.06697.x
    [12]
    肖凌,余曦,汪晓东,等.胸腺肽α1在恶性肿瘤综合治疗中的应用现状[J].西部医学,2010,22(3):561-563. http://www.cnki.com.cn/Article/CJFDTOTAL-XIBU201003075.htm

    Xiao L, Yu X, Wang XD, et al. Application status of thymosin α1 in the comprehensive treatment of malignant tumor[J]. Med J West Chin,2010,22(3):561-563. http://www.cnki.com.cn/Article/CJFDTOTAL-XIBU201003075.htm
    [13]
    胡婷婷,史健.胸腺肽制剂在肿瘤非特异性免疫治疗中应用进展[J].药品评价,2012,9(18):16-19. http://www.cnki.com.cn/Article/CJFDTOTAL-YPPJ201218005.htm

    Hu TT, Shi J. Nonspecific immunity therapeutics of thymopeptide in cancer[J]. Drug Eval,2012,9(18):16-19. http://www.cnki.com.cn/Article/CJFDTOTAL-YPPJ201218005.htm
    [14]
    Garaci E, Favalli C, Pica F, et al. Thymosin alpha 1: from bench to bedside[J]. Ann N Y Acad Sci,2007,1112:225-234. doi: 10.1196/annals.1415.044
    [15]
    朱新锋,陈刚,张文夺,等.肝移植术后应用胸腺肽α1对急性排斥反应的影响[J].中国普外基础与临床杂志,2008,15(6):430-434. http://www.cnki.com.cn/Article/CJFDTOTAL-ZPWL200806018.htm

    Zhu XF, Chen G, Chen WD, et al. Effects of thymosin α1 on acute rejection after liver transplantation[J]. Chin J Bases Clin Gen Surg, 2008,15(6):430-434. http://www.cnki.com.cn/Article/CJFDTOTAL-ZPWL200806018.htm
    [16]
    杨扬,陈规划. 肝脏移植病人术后免疫治疗[J].中国实用外科杂志,2011,31(8):745-747. http://www.cnki.com.cn/Article/CJFDTOTAL-ZGWK201108043.htm

    Yang Y, Chen GH. Postoperative immunotherapy of liver transplant patients[J]. Chin J Pract Surg, 2011,31(8):745-747. http://www.cnki.com.cn/Article/CJFDTOTAL-ZGWK201108043.htm
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(3)  / Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (109) PDF downloads(5) Cited by()
    Proportional views
    Related

    WeChat Subscription Account

    Wechat Service Account

    Contact Us
    • Tel：020-38736410
    • Email: organtranspl@163.com
    • Address：The Third Affiliated Hospital of Sun Yat-sen University, No. 600, Tianhe Road, Tianhe District, Guangzhou
    • Editorial Office of Organ Transplantation  粤ICP备2021030844号
    Links

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return